Wang Jing, Zhang Yaxing, Wang Qiuyuan, Wang Luyao, Zhang Peitong
Guang Anmen Hospital, China Academy of Traditional Chinese Medicine, Beijing 100053, China.
Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China.
Evid Based Complement Alternat Med. 2022 Apr 11;2022:4651432. doi: 10.1155/2022/4651432. eCollection 2022.
We aimed to analyze the possible molecular mechanism of Xihuang pill (XHP) in the treatment of pancreatic cancer based on methods of network pharmacology, molecular docking, and bioinformatics.
The main active components and targets were obtained through the TCMSP database, the BATMAN-TCM database, and the Chemistry database. The active ingredients were screened according to the "Absorption, Distribution, Metabolism, Excretion" (ADME) principle and supplemented with literature. We searched GeneCards, OMIM, TTD, and DrugBank databases for pancreatic cancer targets. The targets of disease and ingredients were intersected to obtain candidate key targets. Then, we constructed a protein-protein interaction (PPI) network for protein interaction analysis and a composition-key target map to obtain essential effective ingredients. Metascape was used to perform functional enrichment analysis to screen critical targets and pathways. The expression and prognosis of key targets were examined and analyzed, and molecular docking was carried out.
A total of 52 active ingredients of XHP, 121 candidate targets, and 52 intersecting targets were obtained. The core active ingredients of XHP for the treatment of pancreatic cancer were quercetin, 17--estradiol, ursolic acid, and daidzein. The core targets were EGFR, ESR1, MAPK1, MAPK8, MAPK14, TP53, and JUN, which were highly expressed genes of pancreatic cancer. Among them, EGFR and MAPK1 were significantly correlated with the survival of pancreatic cancer patients. The key pathway was the EGFR/MAPK pathway. The molecular docking results indicated that four active compositions had good binding ability to key targets.
The molecular mechanism of XHP for the treatment of pancreatic cancer involved multiple components, multiple targets, and multiple pathways. This research theoretically elucidated the ameliorative effect of XHP against pancreatic cancer and might provide new ideas for further research on the treatment of pancreatic cancer.
基于网络药理学、分子对接和生物信息学方法,分析西黄丸(XHP)治疗胰腺癌的可能分子机制。
通过中药系统药理学数据库(TCMSP)、中药系统生物学数据库(BATMAN-TCM)和化学数据库获取主要活性成分和靶点。根据“吸收、分布、代谢、排泄”(ADME)原则筛选活性成分并补充文献。在基因卡片(GeneCards)、在线人类孟德尔遗传数据库(OMIM)、治疗靶点数据库(TTD)和药物银行(DrugBank)数据库中检索胰腺癌靶点。对疾病靶点和成分靶点进行交集分析以获得候选关键靶点。然后,构建蛋白质-蛋白质相互作用(PPI)网络进行蛋白质相互作用分析,并构建成分-关键靶点图以获得关键有效成分。使用Metascape进行功能富集分析以筛选关键靶点和通路。检测并分析关键靶点的表达和预后情况,并进行分子对接。
共获得西黄丸52种活性成分、121个候选靶点和52个交集靶点。西黄丸治疗胰腺癌的核心活性成分是槲皮素、17-β-雌二醇、熊果酸和大豆苷元。核心靶点为表皮生长因子受体(EGFR)、雌激素受体1(ESR1)、丝裂原活化蛋白激酶1(MAPK1)、丝裂原活化蛋白激酶8(MAPK8)、丝裂原活化蛋白激酶14(MAPK14)、肿瘤蛋白p53(TP53)和原癌基因蛋白c-Jun(JUN),这些是胰腺癌的高表达基因。其中,EGFR和MAPK1与胰腺癌患者的生存显著相关。关键通路为EGFR/MAPK通路。分子对接结果表明,4种活性成分与关键靶点具有良好的结合能力。
西黄丸治疗胰腺癌的分子机制涉及多个成分、多个靶点和多条通路。本研究从理论上阐明了西黄丸对胰腺癌的改善作用,可能为进一步研究胰腺癌的治疗提供新思路。